The BCR-ABL tyrosine kinase inhibitor imatinib is effective as a single agent for the treatment of patients in all stages of CML, with the most encouraging results seen in patients in chronic phase (CP) disease. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.